Scynexis (SCYX) Net Income towards Common Stockholders (QoQ) (2013 - 2026)
Powered by 
Analysis
Scynexis (SCYX) Net Income towards Common Stockholders (QoQ) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 56.78% |
| Mar 31, 2026 | -216.64% |
| Dec 31, 2025 | 263.71% |
| Sep 30, 2025 | -24.78% |
| Jun 30, 2025 | -27.71% |
| Mar 31, 2025 | -3,533.76% |
| Dec 31, 2024 | 105.59% |
| Sep 30, 2024 | 80.58% |
| Jun 30, 2024 | -3,617.76% |
| Mar 31, 2024 | 101.23% |
| Dec 31, 2023 | -1,808.65% |
| Sep 30, 2023 | -101.44% |
| Jun 30, 2023 | 460.90% |
| Mar 31, 2023 | -469.06% |
| Dec 31, 2022 | 79.88% |
| Sep 30, 2022 | -121.69% |
| Jun 30, 2022 | -144.82% |
| Mar 31, 2022 | 77.84% |
| Dec 31, 2021 | -3,965.45% |
| Sep 30, 2021 | -136.49% |